Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: A multicenter study

Journal of Rheumatology

Volumn 32, Issue 7, 2005, Pages 1317-1323

  Chevalier, Xavier ^a   Giraudeau, Bruno ^b   Conrozier, Thierry ^c   Marliere, Jocelyne ^b   Kiefer, Philippe ^d   Goupille, Philippe ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d Amgen SA   (France)

Author keywords

Interleukin 1 ; Interleukin 1 antagonist; Intraarticular; Osteoarthritis

Indexed keywords

CHONDROITIN SULFATE; GLUCOSAMINE SULFATE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PIASCLEDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; JOINT EFFUSION; KNEE OSTEOARTHRITIS; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYNOVIAL FLUID LEVEL;

AGED; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; INJECTIONS, INTRA-ARTICULAR; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN; PATIENT SATISFACTION; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SIALOGLYCOPROTEINS;

EID: 22244474585     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Felson DT, Naimark A, Anderson J, Kazis L, Castelli W, Meenan RF. The prevalence of knee osteoarthritis in the elderly: the Framingham Study. Arthritis Rheum 1987;30:914-8.
2. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000;43:1905-15.
3. Chevalier X. Does structural worsening of osteoarthritis predict clinical worsening? Joint Bone Spine 2002;69:430-3.
4. Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS, Woessner JF. Evidence for metalloprotease and metalloprotease inhibitors imbalance in human osteoarthritic cartilage. J Clin Invest 1989;84:678-85.
5. Pelletier JP, Martel-Pelletier J, Abramson SE. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001;44:1237-47.
6. Tetlow LC, Adlam DJ, Wooley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage. Arthritis Rheum 2001;44:585-94.
7. Martel-Pelletier J, McCollum R, Battista JA, et al. The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as type I receptor and analysis of binding kinetics and biological function. Arthritis Rheum 1992;35:530-40.
8. Pratta MA, Scherle PA, Yang G, Liu RQ, Newton RC. Induction of aggrecanase 1 (ADAM-TS4) by interleukin-1 occurs through activation of constitutively produced protein. Arthritis Rheum 2003;48:119-33.
9. Cook JL, Anderson CC, Kreeger JM, Tomlinson JL. Effects of human recombinant interleukin-1 beta on canine articular chondrocytes in three dimensional culture. Am J Vet Res 2000;61:766-70.
10. Pelletier JP, Mineau F, Faure MP, Martel-Pelletier J. Imbalance between the mechanisms of activation and inhibition of metalloproteases in the early lesions of experimental osteoarthritis. Arthritis Rheum 1990;33:1466-76.
11. Arend WP, Malyak M, Cuthbridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16:27-55.
12. Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist deficient mice. J Exp Med 2000;191:313-20.
13. Attur MG, Dave M, Cipolletta C, et al. Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention. J Biol Chem 2000;275:40307-15.
14. Caron JP, Fernandes JC, Martel-Pelletier J, et al. Chondroprotective effect of intra-articular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 1996;39:1535-44.
15. Pelletier JP, Caron JP, Evans C, et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997;40:1012-9.
16. Fernandes JC, Tardif G, Martel-Pelletier J, et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999;154:1159-69.
17. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, McIlwraith CW. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002;9:12-20.
18. Breshinan B, Cobby M. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. Rheumatology Oxford 2003;42 Suppl 2:22-8.
19. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990;46:33-48.
20. Chevret S. The continual reassessment method in cancer phase I clinical trials: a simulation study. Stat Med 1993;12:1093-108.
21. Zohar S, Chevret S. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. Stat Med 2001;20:2827-43.
22. Zohar S, Latouche A, Taconnet M, Chevret S. Software to compute and conduct sequential Bayesian phase 1 or 2 dose ranging clinical trials with stopping. Comput Meth Programs Biomed 2003;72:117-25.
23. Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, de Medicis RC. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol 1996;23:1579-85.
24. 2 activity and cytokine concentration in osteoarthritic synovial fluid. Osteoarthritis Cartilage 1993;1:115-20.
25. Fong KY, Boey WH, Feng PH. Cytokine concentrations in the synovial fluid and plasma of rheumatoid arthritis patients: correlation with bony erosions. Clin Exp Rheumatol 1994;12:55-8.
26. Samad TF, Moore KA, Sapirstein A, et al. Interleukin-1β-mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001;410:471-5.
27. 2 stimulation. Exp Cell Res 1996;222:379-84.
28. Loo M, LaValley M, McAlindon T, Felson DT. Intrarticular hyaluronic acid in the treatment of knee osteoarthritis. JAMA 2003;290:3115-21.